Clinical trial
A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma(HOVON 44 STUDY)
NCT00012051 is registered in ClinicalTrials.gov with Commissie Voor Klinisch Toegepast Onderzoek as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma(HOVON 44 STUDY)
- Lead sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 30, 2000
- Completion date
- October 31, 2007
- Enrollment
- 340 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.